A Study for the Risky Decision-making Deficits Among Methamphetamine Dependence Individuals and Treatment
Conditions: Methamphetamine Use Disorder Interventions: Device: Transcranial direct current stimulation Sponsors: Shanghai Mental Health Center; Wuhan Mental Health Centre; Wuhan Judicial Bureau Hanyang Compulsory Isolated Detoxification Center Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Hypersplenism
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Combination Product: Splenectomy+Targeted therapy+ Immunotherapy Sponsors: Zhiyong Huang; Wuhan Union Hospital, China; Wuhan University; Renmin Hospital of Wuhan University; Taihe Hospital; Hubei Cancer Hospital; Xiangyang Central Hospital of Hubei Province; Wuhan Central Hospital; The Third People ' s Hospital of Yichang City Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Conditions: COVID-19 Interventions: Biological: ARCT-2303; Biological: Influenza vaccine; Biological: Influenza vaccine, adjuvanted; Other: Placebo Sponsors: Arcturus Therapeutics, Inc.; Seqirus; Novotech (Australia) Pty Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
The Safety and Tolerability of WS016 in Healthy Chinese Volunteers
Conditions: Hyperkalemia Interventions: Drug: WS016 Single Dose(6g); Drug: WS016 Single Dose(12g); Drug: WS016 Single Dose(24g); Drug: WS016 Single Dose(36g); Drug: WS016 Single Dose(48g); Drug: SAD matching placebo; Drug: WS016 Multiple Dose(12g); Drug: WS016 Multiple Dose(24g); Drug: WS016 Multiple Dose(48g); Drug: MAD matching placebo Sponsors: Waterstone Pharmaceutical (Wuhan) Co., LTD. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score
Conditions: Myelodysplastic Syndromes Interventions: Drug: Azacitidine Injection Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
Conditions: COVID-19 Pandemic; COVID-19 Vaccines Interventions: Biological: INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg Sponsors: Dr. Soetomo General Hospital; Indonesia-MoH; Universitas Airlangga; PT Biotis Pharmaceuticals, Indonesia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
Conditions: SARS-CoV 2 Pneumonia Interventions: Drug: Calcifediol Sponsors: Complejo Hospitalario Universitario de Albacete Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Experience with a hybrid recruitment approach of patient-facing web portal screening and subsequent phone and medical record review for a neurosurgical intervention trial for chronic ischemic stroke disability (PISCES III)
ConclusionsA tiered approach to eligibility screening using a hybrid of web-based portals to self-identify and screen for general eligibility followed by a more detailed phone and medical record review allowed the study to use fewer sites and reduce cost. Despite the difficult and narrow population of patients suffering moderate chronic disability from stroke, this strategy produced a viable recruitment rate for this invasive study of intracranially injected neural stem cells.Trial registrationClinicalTrials.gov Identifier: NCT03629275 (Source: Trials)
Source: Trials - February 28, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
Conditions: Hyperkalemia Interventions: Drug: WS016 3g; Drug: WS016 6g; Drug: WS016 12g; Drug: Matching Placebo Sponsors: Waterstone Pharmaceutical (Wuhan) Co., LTD. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Effectiveness of a Nasal Spray on Viral Respiratory Infections
Conditions: Acute Respiratory Tract Infection; Flu, Human; COVID-19; Common Cold Interventions: Device: Nasal Spray HSV Treatment Sponsors: CEN Biotech; Urgo Research, Innovation& Development Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Conditions: Ovarian Clear Cell Carcinoma Interventions: Drug: physician ' s choice of chemotherapy; Drug: immune checkpoint inhibitor based therapy Sponsors: Tongji Hospital; Wuhan Union Hospital, China; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei Cancer Hospital; Anhui Provincial Cancer Hospital; Peking University Cancer Hospital& Institute; Hunan Province Tumor Hospital; First Affiliated Hospital of Suzhou Medical College; Shandong Tumor Hospital; Chongqing University Cancer Hospital; First Affiliated Hospital of Zhongshan Medical University; Peking University Shenzhen Hospital Not yet recruiting (...
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
Conditions: Clinical IVb Stage Oral Squamous Cell Carcinomas Patients Interventions: Drug: Adebrelimab Sponsors: Hospital of Stomatology, Wuhan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
COVID-19 Antibody Responses In Cystic Fibrosis
Conditions: COVID-19; Cystic Fibrosis Sponsors: Pilar Azevedo; Queen ' s University, Belfast; European Cystic Fibrosis Society - Clinical Trial Network; Cystic Fibrosis Foundation; Medical University Innsbruck Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects
Conditions: COVID-19 Interventions: Drug: GS-441524; Drug: Placebo Sponsors: National Center for Advancing Translational Sciences (NCATS); Leidos Biomedical Research, Inc.; ICON Government and Public Health Solutions, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
The Aerobic Exercise Capacity and Muscle Strenght in Individuals With COVID-19
Conditions: COVID-19 Pneumonia; COVID-19 Interventions: Device: Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system); Device: Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).; Device: Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.); Device: Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version ...
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
